A dynamic de-escalating dosing strategy to determine the optimal biological dose for antiangiogenic drugs.
Emmenegger
Urban
U
Molecular and Cellular Biology Research, Sunnybrook and Women's College Health Sciences Centre, University of Toronto, Ontario, Canada. urban.emmenegger@swri.ca
Kerbel
Robert S
RS
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D020714:Maximum Tolerated Dose; D009369:Neoplasms / Q000188:drug therapy*; D009389:Neovascularization, Pathologic; D012107:Research Design
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab